Hansa Biopharma
29.52 SEK
+0.14 %
Less than 1K followers
HNSA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Hansa Biopharma
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.7 | 32.3 | 171.3 | 66.4 | 49.1 | 30.8 | 76.0 | 222.3 |
| EBITDA | -116.9 | -173.7 | -637.4 | -93.4 | -154.8 | -147.6 | -124.9 | -520.7 |
| EBIT | -116.9 | -173.7 | -637.4 | -93.4 | -154.8 | -147.6 | -124.9 | -520.7 |
| EBIT-% | -240.3 % | -537.0 % | -372.0 % | -140.8 % | -315.1 % | -479.2 % | -164.4 % | -234.3 % |
| Profit before taxes | -103.7 | -273.6 | -803.7 | -36.7 | -178.0 | -147.6 | -164.6 | -527.0 |
| Net income | -103.8 | -276.4 | -806.7 | -37.1 | -178.9 | -148.3 | -165.0 | -529.3 |